By Jenny Thayer, BioBridges’ Medical, Regulatory, and Scientific Communications SME While an open-minded approach to onboarding new technology is essential to advancing drug and device development, a thoughtless approach...
The New England Chapter will hold its annual Sunday brunch on April 14th at the Hilton Garden Inn in Waltham, MA. This popular event will feature a leisurely late breakfast followed by lively roundtable discussions led by knowledgeable AMWA members who will share their insights, offer valuable advice, and answer questions.
An emerging cellular therapeutics company was entering phase 1 clinical testing for their lead hematology candidate based on their antibody-coupled T-cell receptor (ACTR) technology. In order to move their vision for a singular therapeutic platform approach to treat many different cancers through the development process, they needed a plan, processes and hands-on support.
A large, established pharmaceutical company was planning to submit a new drug application for a biological product to treat a rare disease. Concurrently, the company was working through a variety of corporate initiatives that—while positive—were impacting productivity, including corporate restructure, headquarters relocation, and several acquisition integrations.
